Form 4: Hologic Director Charles J. Dockendorff Reports Stock Transactions

Director Charles J. Dockendorff reported the acquisition of restricted stock units and stock options, as well as the sale of common stock under a pre-arranged trading plan.

Summary

• On March 7, 2024, Charles J. Dockendorff, a director of Hologic Inc., acquired 1,572 restricted stock units (RSUs) that vest on the date of the 2025 Annual Meeting of Stockholders and are settled in shares of common stock.
• Also on March 7, 2024, Dockendorff acquired 4,536 non-qualified stock options with an exercise price of $76.32, which become exercisable on the date of the 2025 Annual Meeting of Stockholders and expire on March 7, 2034.
• On March 8, 2024, Dockendorff sold 1,465 shares of common stock at a price of $76.21 per share.
• The sale was executed pursuant to a pre-existing Rule 10b5-1 trading plan adopted on May 24, 2023.
• Following these transactions, Dockendorff directly owns 1,572 shares of common stock and indirectly owns 15,370 shares through a revocable trust.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing primarily reports routine stock transactions by a company director. The use of a pre-arranged trading plan suggests the transactions were planned and not necessarily indicative of the director's current outlook on the company.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity. It provides transparency to the market regarding the transactions of company insiders, allowing investors to assess management's perspective on the company's value and future prospects. The use of a 10b5-1 trading plan suggests a pre-arranged strategy for stock sales.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading activities.
• The use of Rule 10b5-1 trading plans is a common method for corporate insiders to sell shares without raising concerns about trading on non-public information, similar to practices observed at companies like Medtronic and Abbott Laboratories.
• The vesting schedules for RSUs and stock options are typical, often tied to annual meetings or specific employment milestones, aligning with industry norms seen at companies such as Danaher and Thermo Fisher Scientific.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly diluting the stock due to the issuance of RSUs and options, and potentially affecting the stock price due to the sale of shares.

Key Dates